• RAIPLAY SOUND
  • RAIPLAYLEARNING

report 07 giugno 2021

  • Chi siamo / about us
  • I videogiornalisti

The EBA is an independent EU Authority.  We play a key role in safeguarding the integrity and robustness of the EU banking sector to support financial stability in the EU.

  • Mission, values and tasks

Organisation and governance

  • Governance structure and decision making
  • EBA within the EU institutional framework
  • Internal organisation
  • Accountability

Legal and policy framework

  • EBA regulation and institutional framework
  • Compliance with EBA regulatory products
  • Sustainable EBA
  • Diversity and inclusion
  • Procurement

To contribute to the stability and effectiveness of the European financial system, the EBA develops harmonised rules for financial institutions, promotes convergence of supervisory practices, monitors, and advises on the impact of financial innovation and the transition to sustainable finance.

  • Single Rulebook
  • Implementing Basel III in Europe
  • Supervisory convergence
  • Supervisory disclosure
  • Peer Reviews
  • Breach of Union Law

Direct supervision and oversight

  • Markets in Crypto-assets
  • Digital operational resilience Act

THIRD QUARTER REPORT 2023

Date 30 September 2023 15:29

Third quarter 2023 financial results. Publishing date 07/11/2023

Download Documento

SIX MONTHLY REPORT 2023

Date 30 June 2023 10:45

Six monthly 2023 financial results. Publishing date 19/09/2023

FIRST QUARTER REPORT 2023

Date 31 March 2023 16:37

First quarter 2023 financial results. Publishing date 09/05/2023.

ANNUAL FINANCIAL REPORT 2022

Date 31 December 2022 16:52

Annual Financial Report 2022. Publishing date 20/04/2023

THIRD QUARTER REPORT 2022

Date 30 September 2022 12:44

Third quarter 2022 financial results. Publishing date 09/11/2022.

SIX MONTHLY REPORT 2022

Date 30 June 2022 16:05

Six monthly 2022 financial results. Publishing date 22/09/2022

FIRST QUARTER REPORT 2022

Date 31 March 2022 15:43

First quarter 2022 financial results. Publishing date 11/05/2022.

ANNUAL FINANCIAL REPORT 2021 (.XHTML)

Date 31 December 2021 16:43

Annual Financial Report 2021. Publishing date 29/04/2022. ESEF format XHTML version to open with Microsoft Edge/Google Chrome.

ANNUAL FINANCIAL REPORT 2021 (.ZIP)

Date 31 December 2021 16:39

Annual Financial Report 2021. Publishing date 29/04/2022. ESEF format ZIP version.

ANNUAL FINANCIAL REPORT 2021 (.PDF)

Date 31 December 2021 16:37

Annual Financial Report 2021. Publishing date 29/04/2022. PDF version.

THIRD QUARTER REPORT 2021

Date 30 September 2021 13:42

Third quarter 2021 financial results. Publishing date 09/11/2021

SIX MONTHLY REPORT 2021

Date 30 June 2021 10:08

Six monthly 2021 financial results. Publishing date 16/09/2021

FIRST QUARTER REPORT 2021

Date 31 March 2021 13:22

First quarter 2021 financial results. Publishing date 10/05/2021

Annual Financial Report 2020

Date 31 December 2020 13:41

Annual Financial Report 2020. Publishing date 23/04/2021

THIRD QUARTER REPORT 2020

Date 30 September 2020 13:36

Third quarter 2020 financial results. Publishing date 9/11/2020

Six Monthly Report 2020

Date 30 June 2020 15:23

Six monthly 2020 financial results. Publishing date 21/09/2020

FIRST QUARTER REPORT 2020

Date 31 March 2020 15:39

First quarter 2020 financial results. Publishing date 11/05/2020

Annual Report 2019

Date 31 December 2019 15:41

Third Quarter Report 2019

Date 07 November 2019 12:51

Third Quarter Report 2019 financial results

Six Monthly Report 2019

Date 20 September 2019 14:30

Six monthly 2019 financial results

FIRST QUARTER REPORT 2019

Date 09 May 2019 12:01

First quarter 2019 financial results

Annual Report 2018

Date 31 December 2018 09:00

2018 CONSOLIDATED DISCLOSURE OF NON-FINANCIAL INFORMATION

Date 31 December 2018 08:00

Sustainability Report at 31 December 2018, in accordance with legislative decree no. 254/2016 - Publishing date 04/17/2019

Third quarter report 2018

Date 07 November 2018 13:39

Third quarter 2018 financial results

Six Monthly Report 2018

Date 21 September 2018 11:55

Six monthly 2018 financial results

First quarter report 2018

Date 08 May 2018 14:09

First quarter 2018 financial results – Publishing date 8/05/2018 –

Annual Report 2017

Date 31 December 2017 13:00

Annual Report 2017 Publishing date 20/04/2018 14:38

2017 CONSOLIDATED DISCLOSURE OF NON-FINANCIAL INFORMATION

Date 31 December 2017 11:00

Sustainability Report at 31 December 2017, in accordance with legislative decree no. 254/2016 - Publishing date 04/20/2018

THIRD QUARTER REPORT 2017

Date 30 September 2017 00:00

Third quarter 2017 financial results - Publishing date 11/09/2017 -

SIX MONTHLY REPORT 2017

Date 30 June 2017 00:00

Six monthly 2017 financial results - Publishing date 27/07/2017 -

First quarter report 2017

Date 31 March 2017 00:00

First quarter 2017 financial results - Publishing date 5/11/2017 -

Annual Report 2016

Date 31 December 2016 00:00

Third quarter report 2016

Date 30 September 2016 00:00

Third quarter 2016 financial results

Six Monthly Report 2016

Date 30 June 2016 00:00

Six monthly 2016 financial results

First quarter report 2016

Date 31 March 2016 00:00

First quarter 2016 financial results

Annual Report 2015

Date 31 December 2015 00:00

Third quarter report 2015

Date 30 September 2015 00:00

Third quarter 2015 financial results

Six Monthly Report 2015

Date 30 June 2015 00:00

Six monthly financial results 2015

First quarter report 2015

Date 31 March 2015 00:00

First quarter 2015 financial results

Annual Report 2014

Date 31 December 2014 00:00

Third quarter report 2014

Date 30 September 2014 00:00

Third quarter 2014 financial results

Six Monthly Report 2014

Date 30 June 2014 00:00

Six monthly financial results 2014

First quarter report 2014

Date 31 March 2014 00:00

First quarter 2014 financial results

Annual Report 2013

Date 31 December 2013 00:00

Third quarter report 2013

Date 30 September 2013 00:00

Third quarter 2013 financial results

Six Monthly Report 2013

Date 30 June 2013 00:00

Six monthly financial results 2013

First quarter report 2013

Date 31 March 2013 00:00

First quarter 2013 financial results

Annual Report 2012

Date 31 December 2012 00:00

Third quarter report 2012

Date 30 September 2012 00:00

Third quarter 2012 financial results

Six Monthly Report 2012

Date 30 June 2012 00:00

Six monthly financial results 2012

First quarter report 2012

Date 31 March 2012 00:00

First quarter 2012 financial results

Annual Report 2011

Date 31 December 2011 00:00

Third Quarter Report 2011

Date 30 September 2011 00:00

Six Monthly Report 2011

Date 30 June 2011 00:00

Six monthly financial results 2011

First Quarter Report 2011

Date 31 March 2011 00:00

First quarter 2011 financial results

Annual Report 2010

Date 31 December 2010 00:00

Third Quarter Report 2010

Date 30 September 2010 00:00

Third quarter 2010 financial results

Six Monthly Report 2010

Date 30 June 2010 00:00

Six monthly financial results 2010

First Quarter Report 2010

Date 31 March 2010 00:00

First quarter 2010 financial results

India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration

February 7, 2024 , by Linda Wang

A health provider holds a stethoscope to a child's chest. The child sits on her mother's lap.

Following India's recent approval of NexCAR19, patients with cancer there will soon have access to an affordable CAR T-cell therapy.

In 2015, Alka Dwivedi, then a graduate student at the Indian Institute of Technology (IIT) Bombay, began wondering whether a CAR T-cell therapy could be made in India.

At the time, several CAR T-cell therapies—a type of immunotherapy in which a person’s T cells are modified in a laboratory to selectively kill cancer cells—were being tested in clinical trials in the United States. And although CAR T-cell therapies looked to be promising treatments for blood cancers like leukemia and lymphoma, they could have serious side effects and were expected to carry a high price tag once approved for use.

Both issues, she felt, meant that these cutting-edge treatments—at least in the form in which they were being produced at the time—wouldn’t be a viable option for many people in low- and middle-income countries like India. Dr. Dwivedi and her colleagues envisioned designing a different CAR T-cell therapy, one that could be produced in, and meet the needs of, people with cancer in their country. But they knew they couldn’t do it alone.

Over the next several years, Dr. Dwivedi (who earned her Ph.D. in 2021) embarked on a collaborative journey that brought her and colleagues Rahul Purwar, Ph.D., of IIT Bombay, and Gaurav Narula, M.D., of Tata Memorial Centre in Mumbai, to the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.

During their time at the NIH Clinical Center, this team shadowed leading experts in CAR T-cell therapy at NCI’s Center for Cancer Research. The training provided by NCI scientists—including Nirali Shah, M.D., who studies CAR T-cell therapies for children with blood cancers—proved invaluable, Dr. Dwivedi said. The visit helped guide Dr. Dwivedi and her co-investigators in designing an effective CAR-T cell therapy, actalycabtagene autoleucel (NexCAR19), that could be manufactured in India, made available at a reasonable cost, and meet the needs of patients in India’s health care system.

In October 2023, India’s counterpart to the US Food and Drug Administration, the Central Drugs Standard Control Organization, made NexCAR19 India’s first approved CAR-T cell therapy.

The approval was based on the results of two small clinical trials conducted in India in 64 people with advanced lymphoma or leukemia. According to trial results presented in December 2023 at the American Society of Hematology meeting, 67% of patients (36 out of 53) in the two trials had a notable decrease in the extent of their cancer (objective response), with the cancer disappearing altogether in about half (complete response).

ImmunoACT, a spin-off company of IIT Bombay, funded the trial and will be manufacturing actalycabtagene autoleucel and bringing it to market.

“This is a big achievement for India,” said Dr. Dwivedi, who is now continuing her training in NCI’s Center for Cancer Research. “It’s the team effort that brought us here.”

“This is like a dream come true and an incredible win for the patients in [India],” Dr. Purwar, who was Dr. Dwivedi’s graduate advisor at IIT Bombay and is founder and CEO of ImmunoACT, said in a statement. “Now our patients in India and [other] countries with limited resources will have access to this lifesaving drug at an affordable cost.”

Designing an indigenous CAR T-cell therapy

In India, cancer is rapidly becoming a much bigger public health problem than it once was. According to the most recent estimates, new cancer diagnoses in the country reached nearly 1.6 million in 2023, up from about 980,000 in 2010 . And 800,000 people are estimated to die from cancer each year, a number that is expected to grow substantially in the coming decades .

An illustration of AML cells floating among other cells

One CAR T-Cell Therapy for Blood Cancers?

Using CRISPR, researchers have developed a potential “universal” immunotherapy for blood cancers like leukemia and lymphoma.

Despite this expanding burden of cancer in India, many new cancer treatments are inaccessible because of their high cost and the general lack of insurance coverage among people in India. In addition, some treatments, including CAR T-cell therapy, can cause severe side effects that must be treated in a hospital, further driving up the costs of treatment and requiring access to a nearby hospital, which isn’t the case for many people in the country.

In the United States, six CAR T-cell therapies have been approved to treat blood cancers, primarily lymphomas and some forms of leukemia, and, most recently, multiple myeloma. But these approved therapies all contain antibody fragments derived from mice, which can trigger severe side effects as a patient’s immune system tries to reject the foreign substance.

Using a similar approach to one being pursued by research groups in the United States and elsewhere, Dr. Dwivedi and her colleagues tried modifying CAR T cells to carry a more human-like antibody. They hoped that this “humanized” CAR T-cell therapy would escape immune system attack.

But their initial attempts at designing such a CAR T cell did not work, and they couldn’t figure out why. That’s when they decided to seek outside guidance.

“We thought we should come to NCI and get trained,” Dr. Dwivedi said.

Learning from the leaders

The researchers came to NCI near the end of 2017 through a visiting scientist program sponsored by NCI’s Center for Global Health . In addition to working with Dr. Shah, Terry Fry, M.D., and their colleagues to learn more about designing CAR T cells, the group also worked with Steven L. Highfill, Ph.D., David F. Stroncek, M.D., and their team from NIH’s Center for Cellular Engineering to get advanced training on manufacturing cellular therapies.

“They wanted to learn the entire process,” said Dr. Shah. That included everything from how to manufacture CAR T cells that are of high-enough quality to be used in humans to how to design a clinical trial to test their therapy.

Dr. Dwivedi said that the experience of shadowing NCI scientists was a turning point for her team. When they returned to India, they successfully manufactured several versions of a humanized CAR T-cell therapy. Dr. Shah and her NCI colleagues also made numerous trips to India to help the IIT Bombay/Tata team as they moved through the manufacturing process.

When Dr. Dwivedi and her colleagues tested the different versions in lab and animal studies, one stood out for its ability to kill cancer cells while limiting the immune-related reactions that can lead to severe side effects . Actalycabtagene autoleucel, like most of the CAR T-cell therapies approved in the United States, targets CD19, a protein that is often produced in large amounts on the surface of leukemia and lymphoma cells.

With what appeared to be a promising treatment in hand, it was time to take the next big step: clinical trials.

Impressive clinical trial results

On June 4, 2021, a patient at Tata Memorial Hospital in Mumbai received the first infusion of actalycabtagene autoleucel, the CAR T-cell therapy that would become NexCAR19. This first part of the clinical trial only included 14 patients, all of whom had B-cell acute lymphoblastic leukemia that had returned or did not respond to standard treatments.

Illustrations of two next-generation CAR T cells

A Next Generation of CAR T-Cell Therapies?

Researchers are devising ways to overcome the limitations of CAR T-cell therapy.

Based on promising results from the first 14 patients, a somewhat larger trial was quickly launched . The combined trials included 64 people with B-cell lymphoma or leukemia.

At the American Society of Hematology meeting, ImmunoACT cofounder Atharva Karulkar, Ph.D., and Hasmukh Jain, M.D., of Tata Memorial Centre, who led the clinical trial, presented data from the trials. Among 53 patients who could be evaluated (38 with lymphoma and 15 with leukemia), 26 of 38 patients with lymphoma (68%) and 10 of 15 patients with leukemia (72%) responded to the treatment. All of the responses in the leukemia group were complete responses—that is, they had no signs of cancer.

None of the 53 participants had the neurologic side effects that are often seen in people treated with the CAR T-cell therapies approved in the United States, and only a small portion (5%) had a severe form of an immune-relate side effects known as cytokine release syndrome.

Only five patients required hospitalization because of side effects.  A pediatric trial in B-cell acute lymphoblastic leukemia is ongoing .

A model for global team science

Dr. Karulkar noted during his presentation that, in the United States, an infusion of CAR T-cell therapy costs about $400,000. By contrast, NexCAR19 is expected to cost around $50,000. ImmunoAct will manufacture the CAR T cells in a facility that’s being built in Mumbai and has plans to develop additional manufacturing sites across India. Initially, their hope is to treat around 1,200 patients a year.

“It is remarkable that they were able to generate a brand new CAR T-cell [therapy] that matched the results … being seen in the United States,” Dr. Shah said. “The fact that they have been able to keep the costs low and come up with a [treatment] that is relatively well tolerated—which is important for the patient population they're going to be treating in India—means that they’re going to [improve] the lives of so many people.”

Dr. Shah pointed out that this achievement goes far beyond developing India’s first CAR T-cell therapy. Through this collaborative effort, Dr. Dwivedi and her colleagues have built something that other low- and middle-income countries can model.

“What Dr. Dwivedi and the team there developed is an entire [cellular therapy] infrastructure,” Dr. Shah said. They’ve proven to public health agencies in other countries that they too are “able to now build [these therapies] from the bottom up.”

Featured Posts

January 3, 2024, by Elia Ben-Ari

December 15, 2023, by Edward Winstead

November 30, 2023, by Shana Spindler

  • Biology of Cancer
  • Cancer Risk
  • Childhood Cancer
  • Clinical Trial Results
  • Disparities
  • FDA Approvals
  • Global Health
  • Leadership & Expert Views
  • Screening & Early Detection
  • Survivorship & Supportive Care
  • February (4)
  • January (6)
  • December (7)
  • November (6)
  • October (7)
  • September (7)
  • February (7)
  • November (7)
  • October (5)
  • September (6)
  • November (4)
  • September (9)
  • February (5)
  • October (8)
  • January (7)
  • December (6)
  • September (8)
  • February (9)
  • December (9)
  • November (9)
  • October (9)
  • September (11)
  • February (11)
  • January (10)
  • History of cooperation
  • Areas of cooperation
  • Procurement policy
  • Useful links
  • Becoming a supplier
  • Procurement
  • Rosatom newsletter

© 2008–2024Valtiollinen Rosatom-ydinvoimakonserni

report 07 giugno 2021

  • Rosatom Global presence
  • Rosatom in region
  • For suppliers
  • Preventing corruption
  • Press centre

Rosatom Starts Life Tests of Third-Generation VVER-440 Nuclear Fuel

  • 16 June, 2020 / 13:00

This site uses cookies. By continuing your navigation, you accept the use of cookies. For more information, or to manage or to change the cookies parameters on your computer, read our Cookies Policy. Learn more

Twitter

Altagamma Studies

  • Institutional Relations
  • SDA Bocconi

Members & Partners

  • Emerging Brands
  • Honorary Members

Members Area

  • Altagamma Academy
  • Press Review

Altagamma is the global landmark for the understanding of the luxury market. Every year the Foundation releases eight researches conducted in partnership with some of the most prestigious international partners. The luxury markets are analysed by looking at demand and supply with specific in-depth analysis and forecasts on consumption, consumer profiling, digital, retail and specific product category.

The access to the reports is reserved to Altagamma Companies. Abstracts are available in the press releases area.

Altagamma Studies

Recent studies

report 07 giugno 2021

The evidence on the market trend and future forecasts in the Altagamma Consensus 2024, presented by Stefania Lazzaroni, General Manager of Altagamma, and created with the support of the most important analysts financial institutions and in the Altagamma-Bain Worldwide Luxury Market Monitor, presented by Claudia D'Arpizio and Federica Levato, Senior Partners of Bain & Company.

report 07 giugno 2021

Positive sentiment and optimistic outlook with 40% True-Luxury consumers expecting to spend more in Luxury in next year. UAE and Saudi Arabia toward doubling the sector size. Distribution: moving toward a fusion of physical and digital. Retail outlets shrinking and concentrated in 25 major cities globally.

report 07 giugno 2021

Distribution: moving toward a fusion of physical and digital. Retail outlets shrinking and concentrated in 25 major cities globally.

report 07 giugno 2021

The Digital Competitive Map  analyzes the digital performance of the Altagamma Members, as well as the major international players in design, hospitality, food, jewelry and fashion. It is the base for the ranking of the Altagamma Digital Awards.

report 07 giugno 2021

Trends, figures and forecast for the worldwide high-end design market

report 07 giugno 2021

The WGSN Trend Forecast presented by Lisa White during the lauch event of NEXT DESIGN PERSPECTIVES 2021

report 07 giugno 2021

A year and a half after the onset of the pandemic, the 8th edition of the Altagamma-BCG study takes a deep look into the evolution of the high-end consumer behavior.

report 07 giugno 2021

The proven tool, developed by Contactlab , for evaluating the digital positioning of luxury brands  which this year measured the performance of 44 brands based on 271 parameters.

report 07 giugno 2021

Second Edition of the study focusing on the 2019 performance of the Altagamma Brands in more than 35 digital media channels, in 8 categories, with an insight on the Covid-19 phase.

report 07 giugno 2021

Presented by Luca Solca, Bernstein. 

report 07 giugno 2021

Altagamma Forecast on the Worldwide Personal Luxury Goods Industry in 2020

report 07 giugno 2021

Accenture  partnered with Altagamma to design the Social Luxury Index and track the performance through a dedicated platform.

The analysis focuses on 2018 spontaneous public conversations (mentions)  on top global social media and most relevant blogs.

report 07 giugno 2021

An overview on the Digital Luxury Market, with insight on the importance of Omnichannel, the new luxury channel ecosystem, the Brand storytelling in a digital age and  the new technologies to guarantee authenticity and provenance.

report 07 giugno 2021

The digital postitioning of Luxury Brands

Forecast on the Worldwide Personal Luxury Goods Industry in 2019, according to the main analysts. Apparel and Art de la Table are expected to grow slightly higher than November forecasts. The highest growth rate is expected for Accessories: +7%. Beauty products and hard luxury are forecast to grow steadily.

report 07 giugno 2021

T he global personal luxury goods market reached a “new normal” pattern of growth, following back-to-back years of strong performance in 2017 and 2018. In 2018, 6 percent global growth (at a constant exchange rate) led to €260 billion in sales, which is expected to balloon to €271-276 billion in 2019, registering an expected 4 percent to 6 percent growth at constant exchange rates

report 07 giugno 2021

18.5 million elite consumers (4% of the total) account for 30% of luxury consumption in the world (€920 billion in 2018). The Second-Hand Market and Collaborations between brands are the new trends. Good news for ‘Made In Italy’ whose positive reputation has grown compared with that of French products.

report 07 giugno 2021

While digital technology opens the door to new protagonists and new formats, competition for the most attractive locations remains high with advantages for mega brands and strong pressure on costs, investments and sales.

The personal luxury goods market recorded a solid performance in 2018, with a rise of 2% in Euros, and 6% at constant rates : so growth was unchanged growth in percentage real terms compared to the previous year.

report 07 giugno 2021

With a 5% growth forecast for next year, personal luxury goods consumption are confirmed in constant growth, regardless a series of political and economic exogenous factors that has become more threatening in the second half of 2018 and may have a further impact at the end of next year

report 07 giugno 2021

After a positive 2017, in the first nine months of 2018, Tax-Free Shopping in Europe recorded a downturn in sales (6%), attributable primarily to the appreciation of the Euro against the main currencies, particularly the dollar and the Chinese renminbi. Against a fall in the number of transactions, the Global Blue figures however registered an increaseof 2% in the value of the average European receipt.

According to the Altagamma Monitor of the World Markets, the global market of high-end personal goodswill reach €276-281 billion in 2018, with a constant growth rate of between 6% and 8%. “ China ” and “ millennial state of mind ” are the key words of the positive trend of a healthy market, which will reach a total of €390 billion in 2025, growing at a mean annual rate of 4-5%.

report 07 giugno 2021

The Altagamma Consensus 2018 indicates significantly higher consumption growth forecasts (5%-6%) than the October 2017 forecasts.  With regard to the product categories, a considerable if not unexpected growth forecast for leather bags, shoes and accessories (+7%)is recorded. The 7% growth of jewels and watches is more unexpected. Apparel is expected to grow by +3%, an average between the excellent performance of more creative collections and the more traditional collections, the latter growing only slightly. A growth rate of +3% is forecast for fragrances and cosmetics, more than in past years.   

report 07 giugno 2021

The market of the fifteen most important wine drinking countries is worth €160 billion, with the Top Wines segment representing approximately 7% with a value of €11 billion.The United States represents the largest market at €36 billion (with top wines constituting 9%), while in Europe Italy stands in second place at €13.1 billion (top at 8%), behind France (€22.5 billion, top at 15%) and after Spain (€8.7 billion, top at 5%).

report 07 giugno 2021

The study confirmed the strategic pre-eminence of the on-line market: the digital distribution of luxury products has now reached an inflection point, beyond which we expect a rapid acceleration in growth. Physical retail is swiftly becoming a concept of the past, which needs to be built into the development of digital technologies.

report 07 giugno 2021

30% of total luxury consumption around the world (€900bn, +6%) is made by only 18 million elite consumers. Chinese and millennials are the main factors behind both current growth and that estimated in 2024 (€1,260bn). The key players are nouveaux riches from emerging countries and the young inhabitants of the world’s great metropolises.

Altagamma Studies archive

Another Trump case at the Supreme Court? His argument for immunity could be a tough sell

WASHINGTON – Former President Donald Trump is expected to try to appeal Tuesday's scathing lower court ruling that said he isn't immune from charges that he tried to unlawfully overturn the 2020 election. He may not get a sympathetic audience with the Supreme Court.

A three-judge panel of the D.C. Circuit Court of Appeals on Tuesday forcefully rejected Trump's claim of immunity from prosecution for the potential crimes tied to trying to stay in office despite losing the election.

Trump is expected to appeal that decision to the Supreme Court, with the dual aim of pushing his expansive vision of presidential immunity and delaying his federal trial for allegedly attempting to steal the 2020 election − ideally until after he has regained the White House, and with it the power to order the Department of Justice to drop its charges.

Many legal scholars say the Supreme Court is unlikely to embrace Trump's expansive immunity claims. And the appeals court has taken measures to limit Trump's ability to delay his trial by setting a Monday deadline for Trump to ask the Supreme Court to keep his case on hold.

“I think there’s a strong chance the Supreme Court will unanimously uphold this,” Michael Waldman, president of the Brennan Center for Justice at New York University's law school, told USA TODAY. "The question to me is not how the court will rule, but when."

Prep for the polls: See who is running for president and compare where they stand on key issues in our Voter Guide

A Supreme Court review could move briskly or run for months, depending on how swiftly the justices want to act.

A trial date in limbo

Of the four criminal cases Trump is currently facing, special counsel Jack Smith's case against Trump for allegedly illegally attempting to overturn the election was slated by late last year to be Trump's first 2024 criminal trial.

Customary deadlines for filing Supreme Court arguments run for months at a time and routine cases filed at this point in the year could be heard in the fall, which could potentially put off a decision into 2025. The high court previously declined in December a request from Smith to review Trump's appeal immediately, before the Circuit Court weighed in .

U.S. District Judge Tanya Chutkan had scheduled Trump's trial for March 4, but suspended pre-trial deadlines and eventually postponed the trial date as Trump's appeal unfolded. The appeals court said the suspension will expire Monday unless Trump asks the Supreme Court to keep it in place by then. At that point, it will be up to the high court whether to keep the case on hold while it decides whether to hear the case.

"It puts the Supreme Court in the hot seat, gives Trump only six days to write this petition on an emergency basis, and it's going to be one of the most significant things that the Supreme Court does in relation to the 2024 election,” said Rick Hasen, a professor and election law expert at the University of California, Irvine School of Law, on CNN International.

Waldman said the Supreme Court might not take the case, which would leave the appeals court decision in place, but the high court is also capable of moving cases quickly within days or weeks. In Bush v Gore, which determined the outcome of the 2000 election, the Florida Supreme Court had ordered a hand recount of ballots on Dec. 8, 2000, and the U.S. Supreme Court halted the count on Dec. 12. In the latest case, the Colorado Supreme Court ordered Trump off the ballot on Dec. 19, 2023, Trump appealed Jan. 3 and the Supreme Court set arguments for Feb. 8 .

A strategic dilemma for Trump

Trump could try to slow the process down even further by asking the full D.C. Circuit of 11 judges to consider the case before the Supreme Court. But Chutkan could schedule a trial if he chooses that route, unless the full D.C. Circuit grants him a new stay while that is adjudicated. The full circuit also could refuse to hear Trump's case and let the panel's decision stand.

If Trump heads straight to the Supreme Court and it agrees to hear the case, at least five of the nine justices would need to agree to continue postponing the trial.

“The Supreme Court can move quickly," Waldman said. "And the presidency is at stake. Voters have a right to know if Trump will be convicted."

Expansive immunity claim met with skepticism

Trump's lawyers argued at the appeals court for near absolute immunity. Even if a president killed a political rival, the House would have to impeach and the Senate convict before a president could be criminally prosecuted, according to Trump lawyer John Sauer.

“If there’s no impeachment ever, and no conviction, then the official acts are immune, period,” Sauer said.

The D.C. Circuit Court's panel flatly rejected that assertion when it comes to potential crimes committed in an attempt to retain power.

"We cannot accept former President Trump’s claim that a President has unbounded authority to commit crimes that would neutralize the most fundamental check on executive power — the recognition and implementation of election results," the panel said.

Some experts argued the panel's ruling was made more powerful by coming through one voice: the three judges didn't identify who wrote the unanimous decision.

Many say the Supreme Court is likely to agree with the lower court, at least when it comes to Trump's broadest immunity claims.

“This is a landmark case, but in many ways it is an easy case," Waldman said.

Noting that one of the judges on the panel was appointed by former President George H.W. Bush, a Republican, Waldman added, “It’s very strongly worded and strongly argued and was unanimous with appointees from presidents of different parties. It’s hard to just sneer at it and say it’s just a liberal plot."

Even though six of the nine Supreme Court justices were appointed by Republicans, including three appointed by Trump, experts say that doesn't guarantee Trump will prevail. Trump has lost other cases before the court , such as rejecting a Texas lawsuit aimed at overturning election results in four states.

Norman Eisen, a Brookings Institution senior fellow who served as special counsel to the House Judiciary Committee during Trump's first impeachment, told USA TODAY it "can't be right" that a president has an absolute right to commit crimes while in office.

"Think of the bizarre consequences of planning murders or kidnappings or bank robberies from the Oval Office," he said.

Stanford law professor David Sklansky characterized Trump's immunity argument as "totally meritless."

"It's an argument that is completely inconsistent with the idea that no one is above the law," Sklansky said.

Trump continues to press for immunity

Trump and his supporters argue presidents must be protected from criminal charges after they leave office, or it will inhibit a president's actions in the White House.

Trump characterized the appeals court decision as "Nation-destroying" on his social media platform, Truth Social, posting that a president "must have Full Immunity in order to properly function and do what has to be done for the good of our Country."

Republican Rep. Jim Jordan, a Trump ally and head of the House Judiciary Committee, said the appeals decision “raises serious concerns” that would have to be addressed on appeal.

“That a President is stripped of his constitutional protections for official acts while in office is obviously something that will need to be addressed on appeal,”  Jordan, R-Ohio, said in a post on X .

The Appeals Court countered that the separation of powers means the judicial branch must retain some ability to check the president.

"The court dismantled these claims patiently, painstakingly, and unsparingly," wrote George Conway, an anti-Trump Republican and longtime federal litigator, in the Atlantic .

"The separation of powers doctrine … necessarily permits the Judiciary to oversee the federal criminal prosecution of a former President for his official acts because the fact of the prosecution means that the former President has allegedly acted in defiance of the Congress’s laws," the judges wrote.

Trump continues to push for presidential immunity, despite his own past lawyers arguing otherwise

Courts have never settled the issue of post-White House presidential immunity for crimes committed while in office because no former president has ever been charged before. But many legal experts say the possibility always existed, which is why former President Gerald Ford pardoned former President Richard Nixon.

The appeals court noted that at Trump's second Senate impeachment trial, on a charge he incited the Capitol attack on Jan. 6, 2021, his own lawyers argued the charges should be heard instead in the criminal justice system.

“We have a judicial process in this country,” Trump lawyer David Schoen told the Senate on Feb. 9, 2021. “We have an investigative process in this country to which no former officeholder is immune. That is the process that should be running its course.”

Trump has argued that his alleged conduct under the federal election indictment formed part of his official acts as president.

However, Josh Blackman, a professor at the South Texas College of Law Houston, expressed skepticism about characterizing Trump's rally on Jan. 6, soon before the breach of the Capitol, as part of official conduct.

"As I look at the January 6 speech, and I said this on January 7th, this was a private act," Blackman said. "Because he was talking to supporters, he was not within the outer bounds of his official duties."

Trump's appeals could prevent decision before election: legal experts

Chutkan has already halted pretrial work on Trump's case for two months. She wrote in a January order that Trump would not lose any preparation time for his trial, meaning that even if the Supreme Court declines to hear Trump's appeal and Chutkan restarts the clock within a few weeks, the trial could not begin before early May.

If the Supreme Court agrees to hear the case and continues to postpone the trial, it could take weeks for Trump and Justice Department special counsel Jack Smith to file written arguments and then hold oral arguments. If the high court spent months collecting arguments, the eventual decision creeps closer to the election − and possibly past it.

“Everyone understands that this could well be what determines whether or not Trump can win the election, whether or not he’s going to be convicted of these crimes," Hasen said on CNN International.

  • RAIPLAY SOUND
  • RAIPLAYLEARNING
  • Nessun risultato per

 alt=

  • La mia lista
  • Gestisci account
  • Disconnetti

Genere Film - RaiPlay

  • ACCEDI REGISTRATI

 alt=

  • Privacy Policy

Report - Stagione 2021-2022 - Puntate

  • Regia: Claudio Del Signore
  • Conduce: Sigfrido Ranucci

Report - RaiPlay

  • Vacation Rentals
  • Restaurants
  • Things to do
  • Elektrostal Tourism
  • Elektrostal Hotels
  • Elektrostal Bed and Breakfast
  • Elektrostal Vacation Rentals
  • Flights to Elektrostal
  • Elektrostal Restaurants
  • Things to Do in Elektrostal
  • Elektrostal Travel Forum
  • Elektrostal Photos
  • Elektrostal Map
  • All Elektrostal Hotels
  • Elektrostal Hotel Deals
  • Elektrostal Hostels
  • Elektrostal Business Hotels
  • Elektrostal Family Hotels
  • Elektrostal Spa Resorts
  • 3-stars Hotels in Elektrostal
  • Elektrostal Hotels with Game room
  • Elektrostal Hotels with Banquet hall
  • Hotels near Electrostal History and Art Museum
  • Hotels near Park of Culture and Leisure
  • Hotels near Statue of Lenin
  • Hotels near Museum and Exhibition Center
  • Hotels near Museum of Labor Glory
  • Hotels near (ZIA) Zhukovsky International Airport
  • Hotels near (VKO) Vnukovo Airport
  • Hotels near (DME) Domodedovo Airport
  • Secrets Moxche Playa del Carmen
  • Mohonk Mountain House
  • The LINQ Hotel + Experience
  • ARIA Resort & Casino
  • Secrets Royal Beach Punta Cana
  • The Westin Reserva Conchal, an All-Inclusive Golf Resort & Spa
  • Resorts Hedonism (Hedonism II Resort)
  • Hyatt Ziva Cap Cana
  • Hotel Xcaret Mexico
  • Disney's Animal Kingdom Lodge
  • Hilton Hawaiian Village Waikiki Beach Resort
  • Luxor Hotel & Casino
  • Barcelo Bavaro Palace All Inclusive Resort
  • Excellence Oyster Bay
  • Hotel Riu Republica
  • Popular All-Inclusive Resorts
  • Popular Beach Resorts
  • Popular Family Resorts
  • Popular All-Inclusive Hotels
  • Popular Hotels With Waterparks
  • Popular Honeymoon Resorts
  • Popular Luxury Resorts
  • Popular All-Inclusive Family Resorts
  • Popular Golf Resorts
  • Popular Spa Resorts
  • Popular Cheap Resorts
  • All Elektrostal Restaurants
  • Cafés in Elektrostal
  • Chinese Restaurants in Elektrostal
  • European Restaurants for Families in Elektrostal
  • European Restaurants for Large Groups in Elektrostal
  • European Restaurants for Lunch in Elektrostal
  • Fast Food Restaurants in Elektrostal
  • French Restaurants in Elektrostal
  • Italian Restaurants in Elektrostal
  • Japanese Restaurants in Elektrostal
  • Pizza in Elektrostal
  • Russian Restaurants in Elektrostal
  • Seafood Restaurants in Elektrostal
  • Vegetarian Restaurants in Elektrostal
  • GreenLeaders
  • Elektrostal
  • Things to Do
  • Travel Stories
  • Rental Cars
  • Add a Place
  • Travel Forum
  • Travelers' Choice
  • Help Center
  • Europe    
  • Russia    
  • Central Russia    
  • Moscow Oblast    
  • Elektrostal    
  • Elektrostal Restaurants    

Ratings and reviews

Location and contact.

report 07 giugno 2021

PEKIN, Elektrostal - Lenina Ave. 40/8 - Restaurant Reviews, Photos & Phone Number - Tripadvisor

report 07 giugno 2021

Russia establishes special site to fabricate fuel for China’s CFR-600

!{Model.Description}

A special production site to fabricate fuel for China’s CFR-600 fast reactor under construction has been established at Russia’s Mashinostroitelny Zavod (MSZ - Machine-Building Plant) in Elektrostal (Moscow region), part of Rosatom’s TVEL Fuel Company. 

As part of the project, MSZ had upgraded existing facilities fo the production of fuel for fast reactors, TVEL said on 3 March. Unique equipment has been created and installed, and dummy CFR-600 fuel assemblies have already been manufactured for testing.

The new production site was set up to service an export contract between TVEL and the Chinese company CNLY (part of China National Nuclear Corporation - CNNC) for the supply of uranium fuel for CFR-600 reactors. Construction of the first CFR-600 unit started in Xiapu County, in China's Fujian province in late 2017 followed by the second unit in December 2020. The contract is for the start-up fuel load, as well as refuelling for the first seven years. The start of deliveries is scheduled for 2023.

“The Russian nuclear industry has a unique 40 years of experience in operating fast reactors, as well as in the production of fuel for such facilities,” said TVEL President Natalya Nikipelova. “The Fuel Division of Rosatom is fulfilling its obligations within the framework of Russian-Chinese cooperation in the development of fast reactor technologies. These are unique projects when foreign design fuel is produced in Russia. Since 2010, the first Chinese fast neutron reactor CEFR has been operating on fuel manufactured at the Machine-Building Plant, and for the supply of CFR-600 fuel, a team of specialists from MSZ and TVEL has successfully completed a complex high-tech project to modernise production,” she explained.

A special feature of the new section is its versatility: this equipment will be used to produce fuel intended for both the Chinese CFR-600 and CEFR reactors and the Russian BN-600 reactor of the Beloyarsk NPP. In the near future, the production of standard products for the BN-600 will begin.

The contract for the supply of fuel for the CFR-600 was signed in December 2018 as part of a governmental agreement between Russia and China on cooperation in the construction and operation of a demonstration fast neutron reactor in China. This is part of a wider comprehensive programme of cooperation in the nuclear energy sector over the coming decades. This includes serial construction of the latest Russian NPP power units with generation 3+ VVER-1200 reactors at two sites in China (Tianwan and Xudabao NPPs). A package of intergovernmental documents and framework contracts for these projects was signed in 2018 during a meeting between Russian President Vladimir Putin and Chinese President Xi Jinping.

  • Terms and conditions
  • Privacy Policy
  • Newsletter sign up
  • Digital Edition
  • Editorial Standards

report 07 giugno 2021

IMAGES

  1. Report replica 7 giugno 2021 in streaming e su Rai3. La puntata calcio

    report 07 giugno 2021

  2. Prima pagina de La Gazzetta Dello Sport del 07 giugno 2021

    report 07 giugno 2021

  3. 7 Giugno 2021

    report 07 giugno 2021

  4. Calendario giugno 2021

    report 07 giugno 2021

  5. Report mercati finanziari giugno 2021

    report 07 giugno 2021

  6. Calendario giugno 2021

    report 07 giugno 2021

COMMENTS

  1. Report 2021

    Report Puntata del 07/06/2021 St 2021 109 min In apertura l'inchiesta "I padroni del calcio", corruzione, riciclaggio, conflitti di interesse: sarebbero questi i mali che affliggono il calcio italiano ed europeo.

  2. Report

    Report. 2024 Italia. RIPRODUCI. Il programma che ha fatto la storia nell'ambito del giornalismo investigativo in tv. Sigfrido Ranucci e la squadra di Report ancora una volta in prima fila con inchieste e approfondimenti su politica, economia e società. Regia: Claudio Del Signore.

  3. The Fed

    Adopted effective January 24, 2012; as amended effective January 26, 2021. The Federal Open Market Committee (FOMC) is firmly committed to fulfilling its statutory mandate from the Congress of promoting maximum employment, stable prices, and moderate long-term interest rates. The Committee seeks to explain its monetary policy decisions to the ...

  4. Report

    Puntate Il programma che ha fatto la storia nell'ambito del giornalismo investigativo in tv. Sigfrido Ranucci e la squadra di Report ancora una volta in prima fila con inchieste e approfondimenti su politica, economia e società.

  5. EBA publishes its Report on management and supervision of ESG risks for

    The Report proposes a phase-in approach, starting with the inclusion of climate-related and environmental factors and risks into the supervisory business model and internal governance analysis, whilst encouraging institutions and supervisors to build up data and tools to develop quantification approaches to increase the scope of the supervisory ...

  6. Ministero della Salute

    Report Vaccini Anti COVID-19 Campagna vaccinale Autunno-Inverno 2023/2024 I dati sono aggiornati su base settimanale e sono disponibili in formato aperto con il dettaglio giornaliero. Ultimo aggiornamento dati Totale somministrazioni con vaccino adattato XBB 1.5 Il dato può subire variazioni negative a seguito di rettifiche da parte delle regioni.

  7. IMF Country Report No. 21/101 ITALY

    • The Staff Report prepared by a staff team of the IMF for the Executive Board's consideration on May 26, 2021, following discussions that ended on March 29, 2021, with the officials of Italy on economic developments and policies. Based on information available at the time of these discussions, the staff report was completed on May 11, 2021.

  8. Renewables 2021 Global Status Report

    RENEWABLES 2021 GLOBAL STATUS REPORT A comprehensive annual overview of the state of renewable energy. Start reading the FULL REPORT Access the KEY MESSAGES for decision makers. Chapters; ... 07 Energy Efficiency, Renewables and Decarbonisation; 08 Feature: Business Demand for Renewables; Access the KEY MESSAGES

  9. Report 7 Giugno 2021

    About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features NFL Sunday Ticket Press Copyright ...

  10. 2021 G7 Leaders' communiqué: Our shared agenda for global action to

    Comunicato stampa 13 giugno 2021 15:25 2021 G7 Leaders' communiqué: Our shared agenda for global action to build back better We, the leaders of the Group of Seven, met in Cornwall on 11-13 June 2021 determined to beat COVID-19 and build back better.

  11. EUR-Lex

    RACCOMANDAZIONE (UE) 2021/1004 DEL CONSIGLIO. del 14 giugno 2021. che istituisce una garanzia europea per l'infanzia. IL CONSIGLIO DELL'UNIONE EUROPEA, visto il trattato sul funzionamento dell'Unione europea, in particolare l'articolo 292, in combinato disposto con l'articolo 153, paragrafo 1, lettera j), e paragrafo 2,

  12. Reports

    8.07 MB : BPS_NonFinancialStatement_2021.pdf: FY : Annual report 2021 : 13.95 MB : BPS_Annual_Def_EN.pdf: FY : Annual financial report year 2021 - ESEF format : 45.22 MB : Bilancio Banca Popolare di Sondrio (ESEF)_0.zip: 9M : Consolidated interim report on operations at 30 September 2021 : 738.92 KB

  13. Reports

    Annual Financial Report 2021. Publishing date 29/04/2022. ESEF format ZIP version. ANNUAL FINANCIAL REPORT 2021 (.PDF) Date 31 December 2021 16:37. ... Third quarter report 2018. Date 07 November 2018 13:39. Third quarter 2018 financial results. Six Monthly Report 2018. Date 21 September 2018 11:55.

  14. India's First Homegrown CAR T-Cell Therapy

    On June 4, 2021, a patient at Tata Memorial Hospital in Mumbai received the first infusion of actalycabtagene autoleucel, the CAR T-cell therapy that would become NexCAR19. This first part of the clinical trial only included 14 patients, all of whom had B-cell acute lymphoblastic leukemia that had returned or did not respond to standard treatments.

  15. Report 2021

    Report Puntata del 14/06/2021. In apertura di puntata l'inchiesta "Il segreto in fondo al mare" sui fondali dello Jonio calabrese da ottanta anni giace il relitto di un piroscafo militare affondato durante la seconda guerra mondiale e carico di tritolo che sarebbe stato usato dalla 'ndrangheta per i suoi attentati in Calabria e, in base ad ...

  16. Rosatom Starts Life Tests of Third-Generation VVER-440 Nuclear Fuel

    Rosatom Starts Life Tests of Third-Generation VVER-440 Nuclear Fuel. 8 139. "Introduction of RK3+ will make it possible to operate all four power units at increased thermal capacity and also to extend the fuel cycle at Dukovany NPP, which will improve economic efficiency of the power plant operation", said Alexander Ugryumov, Vice President ...

  17. IR Reports and Presentations

    May 2021. Almaviva S.p.A. and Subsidiaries Consolidated Financial Statements for the years ended December 31, 2020, 2019 and 2018. April 2021. 2020 Q4 Results Presentation. April 2021. Almaviva S.p.A. and Subsidiaries Interim Consolidated Financial Report for nine months period ended 30 September 2020. November 2020.

  18. Altagamma Studies

    Public Report. 05.07.2023. LUXURY RETAIL EVOLUTION. Distribution: moving toward a fusion of physical and digital. ... TRUE LUXURY GLOBAL CONSUMER INSIGHT 2021. A year and a half after the onset of the pandemic, the 8th edition of the Altagamma-BCG study takes a deep look into the evolution of the high-end consumer behavior. ... UPDATE GIUGNO ...

  19. Trump faces tough sell with Supreme Court in appeal of immunity ruling

    The appeals court noted that at Trump's second Senate impeachment trial, on a charge he incited the Capitol attack on Jan. 6, 2021, his own lawyers argued the charges should be heard instead in ...

  20. Report

    Report - Stagione 2021-2022 - Puntate. 2024 Italia. Riproduci. Il programma che ha fatto la storia nell'ambito del giornalismo investigativo in tv. Sigfrido Ranucci e la squadra di Report ancora una volta in prima fila con inchieste e approfondimenti su politica, economia e società.

  21. PEKIN, Elektrostal

    Pekin. Unclaimed. Review. Save. Share. 17 reviews #12 of 28 Restaurants in Elektrostal $$ - $$$ Asian. Lenina Ave., 40/8, Elektrostal 144005 Russia +7 495 120-35-45 Website + Add hours Improve this listing. See all (5) Enhance this page - Upload photos!

  22. Testosteronegenerator

    Testosteronegenerator. Real/full name: Олег Николаев (Oleg Nikolaev) Age: 34 (born Jun 20th, 1989) Place of birth: Russia (Elektrostal, Moscow Oblast) Gender: Male.

  23. Il pacco di Amazon

    0:00 / 18:08 RAI is an Italian public broadcast service. Wikipedia Il pacco di Amazon - Report 14/06/2021 Rai 5.08M subscribers Subscribe 3.4K 399K views 1 year ago...

  24. Russia establishes special site to fabricate fuel for China's CFR-600

    4 March 2021 . Print Email . A special production site to fabricate fuel for China's CFR-600 fast reactor under construction has been established at Russia's Mashinostroitelny Zavod (MSZ - Machine-Building Plant) in Elektrostal (Moscow region), part of Rosatom's TVEL Fuel Company.

  25. MT-07 GIUGNO 2021

    Bellissima Yamaha MT-07 con AbsImmatricolata a giugno 2021 con appena 6.850 KmCilindrata 655Classe emissioni Euro 5Piano tagliandi regolarissimoUltimo taglia...